177Lu-Dotatate Re-Treatment in G1-G2 Gastro-Entero-Pancreatic (GEP) NETs

#1132

Introduction: PRRT is a valid and well tollerated therapy for G1-G2GEP-NETs. A median PFS of >22 mo. has been reported after PRRT and OS of > 5 years is frequent.

Aim(s): Evaluation of toxicity and objective response (OR) of re-treatment with 177Lu-dotatate (Lu-PRRT) in GEP NET responders to 90Y-Dotatoc (Y-PRRT).

Materials and methods: 26 pts were consecutively enrolled into a phase II study of re-treatment with Lu-PRRT. All had previously undergone treatment with Y-PRRT and overall outcome was 1 CR, 3 PR and 22 SD. PFS was 28 mo. (95% CI 20-36). After confirmation of disease progression, pts received 14.8-18.5 GBq of Lu-PRRT in 4/5 cycles. All had conserved kidney and hematological parameters before starting Lu-PRRT.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Severi S

Authors: Stefano S, Maddalena S, Ianniello A, Nicolini S, Caroli P,

Keywords: PRRT, GEP-NET, re-treatment,